Drug Profile
Research programme: inflammation therapeutics - Evotec SE/Interprotein
Latest Information Update: 26 Sep 2019
Price :
$50
*
At a glance
- Originator Evotec AG; Interprotein Corporation
- Class Small molecules
- Mechanism of Action Interleukin 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Inflammation in Europe (PO)
- 25 Nov 2009 This programme is in active development